AbCellera Biologics Inc. Common Shares (ABCL)

Price$5.62

Value ScoreC

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)42.74%

Price vs S&P 500 (4W)7.26%

VGM Score65.07

Market Capitalization$1.72B

All Metrics

Book Value / Share (Quarterly)$3.09

P/TBV (Annual)1.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-46.31%

Cash Flow / Share (Quarterly)$-0.62

Price vs S&P 500 (YTD)56.17%

Net Profit Margin (TTM)-181.75%

EPS (TTM)$-0.48

10-Day Avg Trading Volume8.39M

EPS Excl Extra (TTM)$-0.48

Revenue Growth (5Y)-20.27%

EPS (Annual)$-0.49

ROI (Annual)-15.14%

Net Profit Margin (5Y Avg)-214.23%

Cash / Share (Quarterly)$1.66

Revenue Growth QoQ (YoY)96.34%

ROA (Last FY)-10.79%

Revenue Growth TTM (YoY)242.66%

EBITD / Share (TTM)$-0.63

ROE (5Y Avg)-3.09%

Operating Margin (TTM)-267.61%

Cash Flow / Share (Annual)$-0.58

P/B Ratio1.83x

P/B Ratio (Quarterly)1.13x

Net Income / Employee (Annual)$-260,500

EV / Revenue (TTM)20.69x

Net Interest Coverage (TTM)79.25x

ROA (TTM)-10.62%

EV / EBITDA (TTM)6.71x

EPS Incl Extra (Annual)$-0.49

Current Ratio (Annual)11.32x

Quick Ratio (Quarterly)13.65x

3-Month Avg Trading Volume5.57M

52-Week Price Return137.13%

EV / Free Cash Flow (Annual)3.61x

Revenue / Employee (TTM)$140,900

Tangible BV / Share (Quarterly)$2.96

P/S Ratio (Annual)22.84x

Asset Turnover (Annual)0.06x

52-Week High$6.79

Operating Margin (5Y Avg)-381.08%

EPS Excl Extra (Annual)$-0.49

CapEx CAGR (5Y)23.81%

Tangible BV CAGR (5Y)5.36%

26-Week Price Return50.67%

Quick Ratio (Annual)11.08x

13-Week Price Return56.55%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.05x

Enterprise Value$1.64B

Revenue / Share Growth (5Y)-21.90%

Asset Turnover (TTM)0.06x

Book Value / Share Growth (5Y)0.86%

Revenue / Employee (Annual)$133,700

Pretax Margin (Annual)-236.39%

Cash / Share (Annual)$1.78

3-Month Return Std Dev77.22%

Net Income / Employee (TTM)$-256,100

ROE (Last FY)-15.14%

Net Interest Coverage (Annual)75.61x

EPS Basic Excl Extra (Annual)$-0.49

P/FCF (TTM)4.96x

Receivables Turnover (TTM)2.06x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.48

Receivables Turnover (Annual)1.63x

ROI (TTM)-14.86%

P/S Ratio (TTM)21.67x

Pretax Margin (5Y Avg)-256.28%

Revenue / Share (Annual)$0.25

Tangible BV / Share (Annual)$3.09

Price vs S&P 500 (52W)112.77%

Year-to-Date Return64.33%

5-Day Price Return-13.00%

EPS Normalized (Annual)$-0.49

ROA (5Y Avg)-2.13%

Net Profit Margin (Annual)-194.88%

Month-to-Date Return-8.91%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.65

Operating Margin (Annual)-288.98%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-3.09%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.48

P/TBV (Quarterly)1.17x

P/B Ratio (Annual)1.06x

Pretax Margin (TTM)-219.86%

Book Value / Share (Annual)$3.22

Price vs S&P 500 (13W)48.29%

Beta1.24x

P/FCF (Annual)8.38x

Revenue / Share (TTM)$0.26

ROE (TTM)-14.86%

52-Week Low$2.33

vGradeC

gGradeB

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.14est. -0.20

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.07

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ABCLAbCellera Biologics Inc. Common Shares	C	B	B	$5.62
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

AbCellera is an antibody discovery platform that accelerates clinical candidate identification through proprietary hardware, software, and data science. The company partners with biotechnology and pharmaceutical firms to discover optimized antibody therapies faster and more efficiently than conventional discovery methods. AbCellera's integrated platform reduces time to clinic and de-risks development programs for its partners.